NasdaqGM:IOVABiotechs
A Look At Iovance Biotherapeutics (IOVA) Valuation After Australia’s Conditional Approval For Amtagvi
Iovance Biotherapeutics (IOVA) is back in focus after Australia’s Therapeutic Goods Administration granted conditional approval for Amtagvi, its tumor-infiltrating lymphocyte therapy for adults with previously treated advanced melanoma.
See our latest analysis for Iovance Biotherapeutics.
The TGA decision comes after a volatile period for the stock, with a 30 day share price return of 16.85% and year to date share price return of 67.86%. However, the 3 year total shareholder return has fallen...